Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region

Tuberculosis (TB) Clinical Trial

Official title:

Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00600782
• Other study ID #: 110347
• Status: Completed
• Phase: Phase 2
• Start date: February 5, 2008
• Est. completion date: December 19, 2008

Study information

• Verified date: October 2020
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the safety and immunogenicity of a GSK Biologicals' candidate TB vaccine administered at 0, 1 months to healthy adults living in a TB-endemic region. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: December 19, 2008
• Est. primary completion date: December 19, 2008
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 40 Years

Eligibility

Inclusion Criteria:

• Subjects who the Investigator believes that they can and will comply with the requirements of the protocol.

• A male or female between, and including, 21 and 40 years of age at the time of the first vaccination.

• Written informed consent obtained from the subject prior to any study procedure.

• Free of obvious health problems as established by medical history and clinical examination before enrolment into the study.

• If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.

• No evidence of pulmonary pathology as confirmed by chest X-ray.

• Clinically normal laboratory values for creatinine, ALT, AST and complete blood count.

• Seronegative for human immunodeficiency virus-1 (HIV-1).

• No history of extrapulmonary TB.

• Subjects must have the appropriate PPD skin reactivity (induration measured at 48 to 72 hours after PPD skin test administration).

Exclusion Criteria:

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose.

• History of previous administration of experimental Mycobacterium tuberculosis vaccines.

• History of previous exposure to experimental products containing MPL or QS21.

• Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period.

• Participation in another experimental protocol during the study period.

• Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.

• A family history of congenital or hereditary immunodeficiency. Subjects who describe a first-degree relative with clearly documented autoimmune disease will be excluded

• History of any acute or chronic illness or medication that, in the opinion of the Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine.

• Any chronic drug therapy to be continued during the study period, with the exception of vitamins and/or dietary supplements, birth control pills, anti-histamines for seasonal allergies, SSRIs.

• History of any neurologic disorders or seizures.

• History of allergic reactions or anaphylaxis to previous immunisations.

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.

• History of chronic alcohol consumption and/or drug abuse which in the investigators opinion would put the subject at risk.

• Major congenital defects.

• Pregnant or lactating female.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

Related Conditions & MeSH terms

• Tuberculosis
• Tuberculosis (TB)
• Tuberculosis Vaccines

Intervention

Biological:
• GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)
Intramuscular injection, 2 doses at 0, 1 month

Locations

Country	Name	City	State
South Africa	GSK Investigational Site	Worcester	Western Province

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

South Africa, 

References & Publications (1)

Day CL, Tameris M, Mansoor N, van Rooyen M, de Kock M, Geldenhuys H, Erasmus M, Makhethe L, Hughes EJ, Gelderbloem S, Bollaerts A, Bourguignon P, Cohen J, Demoitié MA, Mettens P, Moris P, Sadoff JC, Hawkridge A, Hussey GD, Mahomed H, Ofori-Anyinam O, Hanekom WA. Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults. Am J Respir Crit Care Med. 2013 Aug 15;188(4):492-502. doi: 10.1164/rccm.201208-1385OC. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence, intensity and relationship to vaccination of solicited local and general symptoms		During the 7-day follow-up period following vaccination after each vaccine dose
Primary	Occurrence, intensity and relationship to vaccination of unsolicited symptoms		During the 30-day follow-up period following vaccination after each vaccine dose
Primary	Occurrence and relationship to vaccination of serious adverse events		During the entire study period
Primary	Haematological and biochemical levels		At protocol defined time points
Secondary	Analysis of cytokine expression by M72-specific CD4+/CD8+ T cells by means of invitro flow cytometry		At protocol defined time points
Secondary	Antibody titres to M72 measured by ELISA		At protocol defined time points